Assessing when to initiate anticoagulation in atrial fibrillation is not improved by including gender, says the ESC in their ...

In this retrospective cohort of patients with atrial fibrillation (AF) who underwent transcatheter aortic valve replacement ...

Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant, today highlighted a key opinion leader presen ...

Uttarakhand government endorses medicinal leech therapy as a non-invasive treatment for post-surgical recovery and skin rejuvenation, amidst growing interest and some controversy.

Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) (the "Company" or "Cadrenal"), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to provide safer and ...

No matter whether patients had CAD or not, the simpler regimen was linked to less mortality and major bleeding at 6 months.

VCM-heparinase was able to reverse heparin effect on viscoelastic parameters during ECMO ... that is focused on improving the safety and availability of blood component therapy. Based in North ...

Sandra Lesenfants, senior vice president of Abbott’s Structural Heart business, shares an update on MitraClip, TriClip, and ...

Pfizer reported earnings that topped expectations Tuesday following an uptick in sales of a Covid-19 therapeutic and gains from other products.

Much of the research in optimizing anticoagulant therapy for acute VTE has been carried out in patients without malignancies. Given the aggressive natural history of VTE in cancer patients ...

The long-standing debate as to when to start anticoagulation in patients with an acute ischemic stroke and atrial fibrillation looks as though it is settled. Abu Dhabi, UAE — The long-standing debate ...

Credit: meeboonstudio / Shutterstock. Patients with atrial fibrillation (AF) who have a stroke may benefit from taking anticoagulants earlier than is currently recommended. This is according to two ...